Acc optima

Quick links to important sections

Acc optima

Treatment option:

Medically reviewed

Laura Arias

Last updated on 22/12/2025

This page provides general, reference-level information compiled from official medical sources. It is not a substitute for professional medical advice, diagnosis, or treatment. For decisions about your health, please consult a qualified healthcare professional.

Overview of Acc optima

Property Description
Active ingredient Acetylcysteine (N-acetylcysteine)
Form Primarily Effervescent tablets (for oral solution)
Pharmacological class Mucolytic agent
Common use Easing clearance of thick respiratory secretions
Origin Synthetic derivative

What is Acc optima and What Class of Drug is it?

Acc optima is a medicinal preparation whose single active substance is acetylcysteine (N-acetylcysteine). It is classified pharmacologically as a mucolytic agent. This classification signifies that the product works primarily by chemically altering the physical characteristics of respiratory secretions. Acetylcysteine itself is a synthetic derivative of the naturally occurring amino acid L-cysteine. This specific preparation is typically positioned as an Over-The-Counter (OTC) product for adults and adolescents.

Understanding Acc optima's Composition and Form

The product functions as a single active ingredient product, deriving its therapeutic capacity exclusively from acetylcysteine. Acc optima is most commonly available as effervescent tablets, which must be dissolved in water to form an oral solution prior to oral administration. The effervescent format is a key delivery system, facilitating dissolution and providing a systemic route for the active compound. The overall composition centers on the active acetylcysteine compound dissolved into an aqueous vehicle.

What is the General Purpose of Mucolytic Agents?

The general purpose of Acc optima's mucolytic agent is to achieve a phlegm-loosening effect to ease symptoms associated with thick respiratory congestion. The active substance executes a direct thiolytic action that cleaves the disulfide bonds within the protein structure of mucus, reducing its viscosity. Acetylcysteine helps to decrease the density of secretions in the respiratory tract. This reduction in the stickiness of the mucus facilitates easier clearance from the airways, thereby supporting normal respiratory function in cases of congestion.

Regulatory References

  1. Public Assessment Report (PAR) for Acetylcysteine

What side effects are possible with Acc optima?

Possible Side Effects and Safety Information

The safety profile of Acc optima, which contains acetylcysteine, is structured around frequency-classified adverse reactions and specific safety constraints documented in official regulatory labeling. Adverse events are grouped by System-Organ Classes (SOCs), reflecting how government authorities categorize effects on the body's systems.


Documented Adverse Reactions

The most commonly reported adverse reactions are classified as uncommon (affecting ge 1/1,000 to < 1/100 people). These frequently involve Gastrointestinal disorders, such as nausea, vomiting, diarrhoea, and abdominal pain. Hypersensitivity reactions (e.g., rash, pruritus) and effects like headache and tinnitus are also categorized as uncommon.


Serious Adverse Reactions and Safety Constraints

Adverse reactions classified as very rare (affecting < 1/10,000 people) include severe outcomes like Anaphylactic shock and severe cutaneous reactions, such as Stevens-Johnson syndrome and Toxic epidermal necrolysis (Lyell's syndrome). Bronchospasm is a rare but serious adverse effect.

Population-Specific Notes

Specific safety considerations exist for certain populations. Patients with Bronchial Asthma must be closely monitored, and treatment must be discontinued immediately if bronchospasm occurs. Due to insufficient data, the use of acetylcysteine is generally avoided during pregnancy as a precautionary measure. Furthermore, the medicine is contraindicated in individuals with a known hypersensitivity to the active substance or excipients.

Exposure Pattern

Official labeling notes that the administration of acetylcysteine may, particularly at the beginning of treatment, liquefy and consequently increase the volume of bronchial secretions.

Overdose and Emergency Response

Overdose and when to seek help

Official regulatory documents define the overdose profile for oral acetylcysteine, the active substance in Acc optima, as one with a low acute systemic toxicity for its mucolytic indication. Regulatory sources note that no toxic overdose has been observed for the oral forms in studies related to this use.

Documented Overdose Manifestations

Acute overdose may result in gastrointestinal symptoms, including nausea, vomiting, and diarrhoea. These effects are generally transient and are the primary manifestations listed in regulatory prescribing information.

Required Emergency Actions

The treatment approach for an overdose is defined as symptomatic and supportive treatment, tailored to the patient’s clinical status. No specific antidote is documented for the mucolytic formulation overdose.

When to Seek Urgent Medical Help:

Urgent medical attention is required in specific scenarios:

  • If the patient is unable to expectorate efficiently due to increased secretions, an open airway must be maintained; this procedure may require immediate medical assistance, such as postural drainage and tracheal suction, as mandated by official labeling.
  • Immediate medical advice must be sought if new cutaneous or mucosal alterations (including signs related to severe dermatological reactions) occur, and treatment must be discontinued immediately.

Therapeutic Uses of Acc optima

What Acc optima Treats: Main Uses and Benefits

Acc optima is a therapeutic option used for supportive care in respiratory conditions that are characterized by excessive production of thick, viscous secretions in the airways. The medication's purpose is to facilitate the loosening and removal of this bronchial mucus.

Its authorized uses center on addressing bronchitis associated with the common cold, where the presence of sticky or heavy phlegm contributes to congestion. The component in Acc optima assists in changing the consistency of the secretions, making them easier to expel and promoting airway clearance.

This supportive measure is intended for individuals experiencing difficulty with expectoration due to the nature of the mucus. The approach is to help maintain open airways and provide relief from symptoms related to mucus buildup.


Quick Facts

  • Supports the management of respiratory conditions with thick mucus.
  • Assists in loosening and removing sticky bronchial secretions.
  • Contributes to airway clearance in cases like acute bronchitis associated with a cold.
  • Provides relief from discomfort caused by viscous phlegm.

Eligibility and Restrictions for Use

Acc optima (acetylcysteine) eligibility is defined by regulatory authorities based on population-specific restrictions, age limits, and conditional use warnings. This information strictly governs who is permitted to use the medicine.

Contraindicated Populations (Must Not Use) Conditional Use (Caution Required)
Children under 2 years of age (risk of airway obstruction) Asthma or history of bronchospasm (treatment must stop if bronchospasm occurs)
Known hypersensitivity to acetylcysteine or any excipients History of peptic ulcer disease (risk of gastric irritation)
Patients with hereditary fructose intolerance (if product contains Sorbitol/Fructose) Patients with Histamine Intolerance (caution for prolonged use)

Age-Group Eligibility:

  • Adults are the primary approved user group for the mucolytic use of this product.
  • The 600 mg effervescent tablet strength is not recommended for children and adolescents under 14 years as its safety and efficacy are not fully established for this high dose in younger age groups.

Pregnancy and Lactation:

Regulatory status indicates that use during pregnancy is not recommended due to limited data, but it may be considered if clearly necessary. Use during breastfeeding may be acceptable, as no adverse effects on the infant are expected at therapeutic doses.

What should I know about interactions with other medicines?

Acc optima Interactions with other medicines and products

The interaction profile of Acc optima (Acetylcysteine) is documented in regulatory sources and primarily involves pharmacodynamic constraints and administration timing requirements.


Documented Pharmacodynamic and Exposure Interactions

  • Nitroglycerin and other organic nitrates: Co-administration may enhance the vasodilatory effects of nitrates, potentially leading to significant hypotension and headache.
  • Antitussive drugs (cough suppressants): These should not be administered concomitantly. This restriction is documented because reducing the cough reflex may lead to a buildup of bronchial secretions.
  • Carbamazepine: Concomitant use may result in sub-therapeutic levels of Carbamazepine.
  • Activated Charcoal: Can decrease the effect of Acetylcysteine by reducing its absorption.

Timing-Based Separation Requirements

Official labeling specifies separation for certain co-administered substances due to potential chemical incompatibility or reduced bioavailability:

  • Oral Antibiotics (e.g., Tetracyclines, Cephalosporins, Penicillins): These should be taken two hours before or after Acetylcysteine. This rule addresses reported in vitro chemical inactivation.
  • Heavy metal salts (e.g., Gold, Iron, Potassium salts): These should not be taken concomitantly but at a different time of the day, as a possible chelating effect may reduce their bioavailability.

Other Administration Constraints

The label states that concomitant intake with food does not affect its effectiveness. However, it is advisable not to mix the oral solution with other medicinal products due to physical incompatibility.

Mechanism of Action

How Acc optima Works: Mechanism of Action

Acetylcysteine is a mucolytic agent whose primary action is purely chemical, focusing on the structural components of respiratory secretions. It operates through two main mechanistic domains that result in distinct physiological consequences.


Direct Chemical Modulation of Mucus Structure (Thiolysis)

This mechanism involves the drug acting directly on the mucin glycoproteins that form the structure of thick mucus. The free sulfhydryl group ( –SH) on the acetylcysteine molecule acts as a reducing agent, chemically cleaving the disulfide bonds ( S-S) that hold the large mucin protein complexes together. This thiolytic action irreversibly breaks down (depolymerizes) the mucus, fundamentally altering its physical properties.


Enhanced Airway Clearance via Modulation of Rheology

The molecular cleavage of mucin results in a reduction in the mucus's viscosity (thickness) and elasticity (stickiness). This change in mucus rheology directly enhances the function of the physiological pathway of mucociliary transport, contributing to enhanced ciliary propulsion and secretion clearance. A secondary mechanism is the drug's role as a precursor for the endogenous antioxidant, Glutathione ( GSH), which contributes to the maintenance of redox balance in the respiratory environment.

Dosage and Administration Information

How to Use Acc optima: Official Administration Guidelines

Acc optima (acetylcysteine) is formulated as effervescent tablets and is strictly intended for oral use after being prepared as an aqueous solution. The official dosing regimen for adults and adolescents aged 12 years and older is a total daily dose of 600 mg of acetylcysteine. This is typically administered as one 600 mg tablet once daily, though some formulations permit a divided dose of 200 mg three times per day.


Preparation and Intake Instructions

For proper administration, the effervescent tablet must be fully dissolved in half a glass of water immediately before consumption, and the resulting solution should be drunk without delay. Official labeling advises taking the dose after meals. To support the action of the medicine, the consumption of plenty of fluids during the day is recommended. Special procedural guidance exists for co-administered medicines, advising that oral antibiotics should be taken at least two hours before or two hours after acetylcysteine to avoid potential inactivation.


Age and Duration Rules

The 600 mg strength of acetylcysteine is not suitable for children under 12 years of age. For individuals who may have difficulty expectorating, such as the elderly or weakened patients, the dose is advised to be taken in the mornings. For acute, self-managed conditions, the maximum duration of use is generally restricted to 4 to 5 days before a medical consultation is required if symptoms persist or worsen.

Recent Clinical Evidence

Research evidence / Overview of studies for Acc optima

The research evidence for Acc optima, which contains the active substance acetylcysteine, was evaluated in studies examining its use in conditions characterized by fluctuating or episodic manifestations of respiratory congestion. The evidence is drawn from clinical evaluations, primarily focusing on research that explored outcomes related to the clearance of thick phlegm.


Evidence for Symptomatic Relief in Acute Respiratory Congestion

The core evidence for this medicine was examined in studies of acute respiratory conditions involving a productive cough. Researchers used high-quality study designs, including randomized controlled trials (RCTs), many of which compared the active substance against an inactive substance (placebo). These individual trial results are summarized in systematic reviews and meta-analyses, which compile and analyze findings from several sources.

In these research scenarios exploring short-term symptom changes, the studies monitored several key patient-reported outcomes describing perceived discomfort. Findings describe patterns observed in the studies related to the ease of phlegm expulsion and changes measured during the study period concerning mucus consistency. However, the evidence is not uniform; findings were mixed across various studies concerning the magnitude of change in these acute, temporary respiratory states.


Evidence in Specific Populations

Research was studied for its application in different age groups, primarily adults and adolescents who had acute cough. Additionally, specific trials have explored the safety profile and short-term symptom patterns in pediatric populations (children generally aged two years and older).

The evidence volume is restricted for very young children (under two years of age), a population for whom data are still emerging. Research indicates that the existing trials provide limited insight into how the active substance was observed in people with complex underlying health issues.


Limitations and Areas of Research Uncertainty

Research data are still emerging concerning acute, short-term relief. One limitation is that the sample sizes were modest in some of the pivotal trials, which can introduce uncertainty into findings when applied broadly. Furthermore, much of the higher-volume research was studied for chronic respiratory disease management, meaning the available data apply only to the populations studied and do not directly address simple, acute bronchitis associated with a cold.

Key Studies & References

  1. PRODUCT MONOGRAPH ACETYLCYSTEINE SOLUTION (Mucolytic Agent)
  2. N-acetylcysteine Treatment in Chronic Obstructive Pulmonary Disease (COPD) and Chronic Bronchitis/Pre-COPD: Distinct Meta-analyses

Frequently Asked Questions (FAQ)

Common questions about Acc optima (FAQ)

Q: Is Acc optima the same type of medicine as [similar drug name]? (high-level)

Acc optima contains the active substance acetylcysteine, which is officially classified as a mucolytic agent. This classification indicates that its primary function is to chemically break down and thin out the consistency of thick respiratory secretions. This is the official designation provided in regulatory documents.


Q: How does the way Acc optima works differ from older medicines for the same condition?

Official documents describe the drug’s action as a thiolytic mechanism. This involves the active substance directly cleaving the protein structures within the mucus, fundamentally reducing its viscosity (thickness). This mechanism of action is described as directly breaking down the protein structure of mucus, which results in the reduction of viscosity (thickness).


Q: What kind of studies support the use of Acc optima?

The official acceptance of acetylcysteine is supported by clinical evaluations, including high-quality research designs such as randomized controlled trials (RCTs). These studies, which are often summarized in systematic reviews, focus on outcomes related to easing the clearance of thick phlegm in acute respiratory conditions.


Q: Can elderly patients generally use Acc optima?

Adults are the primary approved user group for this medicine. Regulatory documents state that adults are the primary approved user group, and specific guidance exists for use in the elderly. Official guidance notes that for elderly or weakened patients, the dose is advised to be taken in the mornings if the individual has difficulty with expectoration.


Q: Are there known interactions between Acc optima and common supplements like vitamins or herbal remedies?

Regulatory documents advise that certain heavy metal salts, such as iron, should not be taken at the same time as Acc optima. While the label does not specify every vitamin or herbal remedy, official documents note possible chemical incompatibility that may affect the bioavailability of certain co-administered substances.


Q: How often do people report feeling nauseous or having stomach issues with Acc optima?

Gastrointestinal issues, including nausea, vomiting, diarrhoea, and abdominal pain, are the most commonly reported side effects. Official data classifies these as uncommon adverse reactions, meaning they are reported in between 1 and 10 out of every 1,000 people.


Q: Does Acc optima interact with birth control pills?

The official interaction profile lists time-separation requirements for substances like certain oral antibiotics due to chemical inactivation. However, regulatory documents do not document a specific interaction or separation requirement for oral contraceptives (birth control pills).


Q: How long does Acc optima stay in the system after the last dose?

The official pharmacokinetic data provides the elimination half-life of the active substance, acetylcysteine, as approximately 5.6 hours in adults. This period is a measure of how quickly the body processes the active substance.


Q: What general instructions are given for storing Acc optima?

Official labeling requires the product to be kept in its original, tightly closed package at all times. This is necessary to protect the tablets from moisture and light. It must also be stored at temperatures not exceeding 30 C.


Q: What happens if Acc optima is taken with grapefruit juice?

Official labeling states that taking the medicine with food does not affect its effectiveness. No specific interaction with grapefruit juice or any other fruit juice is documented in the authorized prescribing information for this medicine.


Q: Why is Acc optima sometimes taken off-schedule or irregularly by patients?

The medicine is officially intended for use in conditions that have fluctuating or episodic manifestations of congestion. For self-managed conditions, regulatory guidelines specify a maximum duration of 4 to 5 days, which supports its use for short-term, acute symptoms rather than continuous, long-term use.


Q: What should be done if a user experiences an unexpectedly strong effect from Acc optima?

Official safety documents include warnings about specific serious adverse effects, such as a severe skin reaction or bronchospasm (sudden difficulty breathing). If serious adverse effects are experienced, regulatory documents specify that the treatment must be discontinued immediately. Users are advised to seek professional medical evaluation in such events.


Q: Does Acc optima have any known effects on a person's mood or energy levels?

The official list of adverse reactions for this medicine does not include changes to a person's mood or energy levels. Any reported central nervous system effects documented in the labeling are limited to the uncommon reports of headache and tinnitus (ringing in the ears).


Q: Is Acc optima known to cause dependency or withdrawal symptoms?

The official regulatory documents do not include any warnings or statements regarding the potential for dependence or the occurrence of withdrawal symptoms upon discontinuation of use.


Q: Can Acc optima be used by women who are pregnant or planning to become pregnant?

Official information states that use during pregnancy is not recommended due to limited available data. For women who are planning to become pregnant, regulatory documents advise that the medicine should be used only if clearly necessary and after consulting with a healthcare professional.


Q: Are there any routine tests that need to be performed while taking Acc optima?

The official labeling does not mandate routine blood work or other laboratory monitoring for patients using the product for its mucolytic indication. Monitoring is only specifically mentioned as a caution for patients who have existing conditions, such as Bronchial Asthma.


Q: How does Acc optima affect blood pressure or heart rate according to clinical data?

The official list of side effects does not include direct effects on heart rate or blood pressure. However, official warnings note that when combined with nitroglycerin (a medicine that widens blood vessels), Acc optima may enhance its effects, which could potentially lead to significant hypotension (low blood pressure).


Q: Why are there different strengths of Acc optima available?

Regulatory documents confirm that the recommended total daily dose of 600 mg is delivered either as one 600 mg tablet once daily or, for some product formulations, as a divided dose of 200 mg taken three times per day. The different strengths are provided to facilitate these distinct, approved dosing regimens.


Q: Is the research evidence for Acc optima considered strong or limited?

Official assessments note that while the evidence for the drug's use comes from high-quality clinical studies, the overall findings were mixed across various acute studies. Assessments also indicate that the evidence volume is restricted for very young children and that sample sizes were modest in some pivotal trials.


Q: Can men with fertility concerns use Acc optima?

The official regulatory documents that define eligibility, safety, and use conditions for this product do not contain any information or warnings regarding the effect of acetylcysteine on male fertility.


Q: Does Acc optima interact with commonly taken over-the-counter pain relievers?

The official interaction profile lists antitussive drugs (cough suppressants) and certain prescription medications as requiring caution. It does not specifically list common over-the-counter pain relievers (such as ibuprofen or paracetamol) as having documented interactions.


Q: If I miss a scheduled dose of Acc optima, what are the general guidelines for next steps?

Official documentation does not provide specific missed dose instructions. Regulatory guidance states that the medicine must be taken according to the approved regimen and should not be taken as a double dose to compensate for a missed one.


Q: How is the efficacy of Acc optima typically measured in clinical research?

Researchers measured efficacy using patient-reported outcomes that described perceived discomfort during the study period. They also used objective assessments focused on the consistency of the mucus and the ease of phlegm expulsion.


Q: Are there groups of people who are excluded from using Acc optima in clinical trials?

Research assessments indicate that the existing trials provide limited insight into how the active substance was observed in people with complex underlying health issues. The studies' primary focus was on otherwise healthy adults and adolescents with acute cough.


Q: Do patients generally need to take Acc optima with food?

Official labeling advises taking the dose after meals. While the label states that concomitant intake with food does not affect its effectiveness, the post-meal timing is the recommended administration condition.


Q: Is a rash or skin reaction a potential side effect of Acc optima?

Yes, hypersensitivity reactions, which include the development of a rash or pruritus (itching), are listed as uncommon side effects. Official documents also note that very rare, severe skin reactions such as Stevens-Johnson syndrome are documented.

How should Acc optima be stored and disposed of?

Official Storage and Disposal Requirements

Acc optima (acetylcysteine effervescent tablets) must be stored under specific conditions mandated by regulatory labeling to maintain stability and safety. The product must be kept in its original package and stored at temperatures not exceeding 30 C.

Protection requirements include keeping the container tightly closed and storing the tablets in a manner that protects from moisture and light.

After the first opening of the container, the product has a defined in-use shelf life, which must be strictly followed. Additionally, the medicine must be stored out of the sight and reach of children at all times.

When disposing of unused or expired product, the official instruction is to not throw away any medicines via wastewater or household waste. Disposal must be completed in accordance with local requirements, and patients should consult a pharmacist for guidance on safe disposal.

Attention! Always consult to a doctor or pharmacist before using pills or medicines.

Equivalent of Acc optima found in:

A-Z Index: